The International IgA Nephropathy Network held the 16th International Symposium on IgA Nephropathy September 21-23 and George Clinical scientific leader Professor Jonathan Barratt presented a key presentation during the first plenary session of the event. Barratt, the Mayer professor of renal medicine at the University of Leicester, presented “RNA Interference in IgAN” on the first day […]
Read MoreCiteline has named George Clinical as a finalist for their 2021 Clinical Research Team of the Year. Citeline, a comprehensive global R&D intelligence firm provides insights into the global clinical trial landscape and the development of clinical trial programs, selected the DARE-19 team of George Clinical based on their compelling international accomplishments during the height […]
Read MoreGlaxoSmithKline recently announced positive headline results from five studies of the Phase III ASCEND program conducted with George Clinical evaluating the efficacy and safety profile of daprodustat, an investigational oral hypoxia-inducible factor prolyl hydroxylase inhibitor (HIF-PHI) for patients with anemia due to chronic kidney disease (CKD). The ASCEND program showed that daprodustat met its primary […]
Read MoreGeorge Medicines, a late-stage drug development company focused on providing innovative and accessible medicines for the world’s leading causes of death and a sister company to George Clinical, has initiated two Phase III trials investigating its proprietary triple combination candidate, GMRx2, as a first-line treatment for hypertension. Recent hypertension guidelines recommend combination therapy as initial […]
Read MoreGeorge Clinical’s deep oncology research expertise was on display during the 2021 ASCO Annual Meeting. Several leaders were featured in sessions during the conference including Drs. Lee Schwartzberg, Ari VanderWalde, Herbert Loong, Ralph Boccia, Timothy Pluard and Jason Chandler. Schwartzberg is a co-author on 10 different abstracts that were highlighted in sessions during the virtual event […]
Read MoreSister organization George Medicines, a late-stage drug development company focused on providing innovative and accessible medicines for the world’s leading causes of death, announced the appointment of Stefan König as Chief Executive Officer. George Medicines, a venture-backed spin-out company from The George Institute for Global Health, one of the world’s leading independent medical research institutes, […]
Read MoreSYDNEY, June 15, 2021 – George Clinical, a global scientifically-backed clinical research organization, and Omico, an Australian-based not-for-profit national precision oncology platform, have aligned to revolutionize oncology clinical trial access for patients and improve the efficiency of study enrollment. The two organizations began collaborating in late 2020 and announced the joint effort during the 2021 […]
Read More
The important achievements of clinical research around the world hold the potential to improve the health and wellness of humanity. Both leading projects day to day as well going the extra mile behind the scenes stand more than 300 of our dedicated, professional project team members across 38 geographical locations throughout the USA, Asia-Pacific region and […]
Read MoreDetailed results from the primary analysis of the DARE-19 Phase III trial assessing the potential of Farxiga (dapagliflozin), a sodium-glucose cotransporter 2 (SGLT2) inhibitor, to treat patients hospitalized with COVID-19 who are at risk of developing serious complications showed that the trial did not achieve statistical significance for the two primary endpoints. However, there were […]
Read MoreBEIJING and SYDNEY, April 29, 2021 – Guangzhou Link Health Pharma Co., Ltd. (Link Health) and George Clinical Pty Ltd (George Clinical) have signed a term sheet to enter into a strategic agreement to establish an independent joint venture clinical development company called Link-George Clinical Research Co., Ltd (Link-George). Link-George will deliver clinical trials for […]
Read More
